Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Slides:

Advertisements

Similar presentations

Kendrick Sparks, PGY3 September 17, 2015

Advertisements

Statin Myopathy (AHA/ACC/NHLBI)

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

PCSK9 Inhibitors Post-CVOTs

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

Cholesteryl Ester Transfer Protein Inhibitors

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

American Heart Association Scientific Sessions

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Statin Selection in Special Patient Populations: A Case Challenge

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

An Update on PCSK9 Inhibitors

Evaluating LDL-C Recommendations

What's New in Dyslipidemia?

62-year-old Man With Unstable Angina

PCSK9 Inhibitors and Cardiovascular Outcomes

% decrease in LDL-C at 24 weeks from baseline

% decrease in LDL-C at 24 weeks from baseline

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

A Patient Journey Through Statin Intolerance

Improving Appropriate Access to PCSK9 Inhibitors

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

New LDL-C Lipid Targets

Radical New Concepts in Lipid Management

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Clinicians' Corner in Dyslipidemia

Updates in Cardiovascular Medicine

Shifting Currents in Hyperkalemia Management 2015 in Review

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Monoclonal Antibodies in CVD: What Does the Future Hold?

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Screening, Lipid Stabilization, and Placebo Run-in

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

Glucose Management and Statin Therapy

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Latest Lipid Guidelines in Perspective

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Reducing Risk for CV Outcomes

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

A Family Affair.

Lipid Updates From Spring 2019

Oral Therapies in MS.

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Glucose Management and Statin Therapy

PCSK9 Inhibitors and Statin Intolerance

Updates on Dyslipidemia

Achieving Lipid Targets With PCSK9 Inhibition

Lipids, the Heart, and the Kidney

PCSK9 Inhibitors and Real-World Evidence

Presentation transcript:

Patient Presentation

PRIMO Study Incidence of Muscle Adverse Effects

Therapy for Statin Intolerance

Ezetimibe Trials

Population Studies PCSK9 Loss-of-Function Mutations

PCSK9-Directed Therapies in Development

GAUSS-1 Phase 2 Evolocumab in Statin-Intolerant Patients

GAUSS-1 % Change in LDL-C From Baseline at Week 12

GAUSS-2 Study Design Phase 3 Efficacy and Safety Study of Evolocumab in Statin-Intolerant Patients

GAUSS-2 % Change in LDL-C From Baseline at Week 12

GAUSS-2 Safety and Tolerability

Abbreviations

References

References (cont)

References (cont)